Most peptides marketed for "focus and clarity" are backed by a handful of rodent studies and a lot of enthusiasm. Semax is different. It has been used clinically in human patients since the 1990s, with a published track record in peer-reviewed neurology journals that spans stroke recovery, cognitive rehabilitation, and neuroprotection. That's a meaningfully deeper evidence base than most peptides get — and it's worth understanding exactly what the research does and doesn't show.

What Semax Actually Is

Semax is a synthetic heptapeptide derived from a fragment of adrenocorticotropic hormone (ACTH) — specifically the ACTH(4-10) region — engineered to retain the hormone's neurological signaling activity while eliminating its steroidogenic (adrenal-stimulating) effects. It was developed at Russia's Institute of Molecular Genetics and has been used in Russian clinical practice for cognitive and cerebrovascular conditions since the 1990s.

Mechanistically, Semax's most well-documented action is upregulating brain-derived neurotrophic factor (BDNF), a protein central to neuroplasticity, learning, and neuronal survival. It's also been shown in animal models to influence dopaminergic and serotonergic signaling, which may explain its broader effects on attention and mood regulation.

The Human Research: What's Actually Been Studied

Semax's clinical history is unusually long for a peptide in this category — so here's what the human data actually shows, and what remains preclinical.

1. Improved Recovery Outcomes After Ischemic Stroke

One of the earliest clinical investigations examined 30 patients with acute hemispheric ischemic stroke treated with Semax (12–18 mg/day depending on stroke severity) alongside standard intensive therapy, compared against patients receiving conventional treatment alone. The Semax group showed measurable differences in the recovery of general cerebral and focal motor deficits, tracked through clinical rating scales, EEG mapping, and somatosensory evoked potentials. This was a human clinical study, though non-randomized — it became the foundational evidence behind Semax's 1990s regulatory approval in Russia for acute ischemic stroke (Gusev et al., Zhurnal Nevrologii i Psikhiatrii, 1997 — human clinical study, n=30 treated vs. 80 comparison).

2. BDNF Levels Track With Functional Recovery

A 2018 study followed 110 patients after ischemic stroke, divided into early and late rehabilitation groups, each further split into Semax and non-Semax subgroups. Patients receiving Semax (two 10-day courses of 6,000 mcg/day) showed sustained increases in plasma BDNF throughout the study period, and higher BDNF levels correlated with better outcomes on the Barthel Index — a standard measure of functional independence. This is a human clinical study, and it's one of the clearest links between a measurable biomarker (BDNF) and real functional recovery in Semax research (Gusev et al., Zhurnal Nevrologii i Psikhiatrii, 2018 — human clinical study, n=110).

3. Reduced Disease Progression in Cerebrovascular Insufficiency

A separate clinical study evaluated Semax in patients with chronic cerebrovascular insufficiency — a condition marked by reduced blood flow to the brain, often preceding stroke. Treatment was associated with clinical improvement, stabilization of disease progression, and a reduced rate of subsequent stroke and transient ischemic attacks over the study period. This was a human clinical study conducted in a real-world neurology patient population, not a healthy-cognition cohort (Gusev et al., Zhurnal Nevrologii i Psikhiatrii, 2005 — human clinical study).

4. The Mechanistic Groundwork: BDNF and Neurotransmitter Signaling

The biological "why" behind these clinical findings comes primarily from animal research. Studies in rats have shown that Semax increases BDNF expression in the hippocampus and frontal cortex within hours of administration, and separately that it activates dopaminergic and serotonergic neurotransmission — a proposed mechanism for its nootropic and mood-related effects. Both of these are preclinical, rodent-model findings, and they explain the pathway; they don't independently prove the human outcome (Dolotov et al., mechanistic rodent study; Eremin et al., Neurochemical Research, 2005 — preclinical, rodent).

What About Healthy Cognitive Performance?

It's worth being direct here: the strongest clinical evidence for Semax is in patients recovering from neurological injury — stroke and cerebrovascular insufficiency — not in healthy adults looking for a cognitive edge. Extrapolating from stroke-recovery data to everyday focus and mental clarity is mechanistically reasonable, given the BDNF and neurotransmitter pathways involved, but it hasn't been directly tested in large trials of healthy subjects. We think that distinction matters, and we'd rather tell you where the evidence actually points than round it up.

Semax + Selank: Why We Pair Them

Selank, developed by the same Russian research institutions, is a tuftsin-derived peptide studied primarily for anxiolytic (anti-anxiety) effects rather than cognitive ones. In a human clinical trial of 62 patients with generalized anxiety disorder and neurasthenia, Selank produced anxiolytic effects that researchers judged comparable to a standard benzodiazepine, without the same sedation profile — though the trial was small and open-label (Kozlovskiy/Semenova et al., Zhurnal Nevrologii i Psikhiatrii, 2008 — human clinical study, n=62). A later study directly comparing Selank to the benzodiazepine phenazepam in anxiety disorder patients found similar tolerability findings (Medvedev et al., Zhurnal Nevrologii i Psikhiatrii, 2014 — human clinical study). Mechanistically, in vitro work suggests Selank's anxiolytic action may involve modulation of GABAergic gene expression, distinct from how benzodiazepines act directly on GABA-A receptors (in vitro, cell-culture study).

Combined, Semax's neurotrophic/cognitive profile and Selank's anxiolytic profile are why we offer them together for clients managing both mental performance and stress load.

Available Through Calibrate IV

We offer Semax and Semax/Selank combinations in a few formats depending on your protocol needs:

• Semax (10mg) — standard vial, ideal for those starting a focus-and-clarity protocol
• Semax (30mg) — higher-yield vial for extended protocols
• Semax & Selank Blend — combined vial for cognitive performance plus stress management
• Selank + Semax Medi-Melts — needle-free sublingual format for daily use

Every protocol starts with a consultation so our clinical team can review your health history and confirm the right fit before anything ships.

Call 1-844-416-2546 or email concierge@calibrateiv.com to schedule a consultation at our Miami, New York, or Las Vegas locations.

This content is for educational purposes only and is not medical advice. Semax and Selank are approved for clinical use in Russia; regulatory status in the United States differs, and human research to date is concentrated in specific patient populations rather than healthy-cognition cohorts. Peptide therapy should only be pursued under the guidance of a licensed healthcare provider.